Epoch Biosciences (AKA: Epoch Pharmaceuticals~Micro-Probe Corporation~Microprobe Corporation~Saigene) Profile last edited on: 11/3/17
CAGE:
UEI:
Business Identifier: Proprietary products to accelerate genomic analysis 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 01
County: Snohomish
Congr. District: 01
County: Snohomish
Public Profile
In September 2004, Epoch Biosciences merged with CA based Nanogen, also an SBIR involved firm. Formerly called Epoch Pharmaceuticals (OTC EPPH ), Epoch Biosciences moved to NASDAQ (EBIO). Epoch Pharmaceuticals Inc. is a biomedical company utilizing nucleoside and nucleotide chemistry to develop molecular tools for genetic analysis. Utilizing unique and proprietary technology in the rational design, synthesis and chemical modification of oligonucleotides, the Company has positioned itself to provide products and techniques for high throughput genetic sequence analysis that are in increasing demand in the rapidly expanding field of genetic pharmacology. Previously, Epoch's therapeutic research and development program had focused on the modification of gene expression by altering cellular genomic DNA using oligonucleotide targeting technology combined with chemical reactivity. Epoch's technology is based on its expertise in designing and synthesizing oligonucleotides bearing modifications that selectively bind to and interact with the target genes.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
250-500Revenue Range
20M-50MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : EBIOIP Holdings
50-74Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2008 | 2 | NIH | $737,945 | |
| Project Title: Solid phase immobilized minor groove binder probes | ||||
| 2003 | 1 | NIH | $100,000 | |
| Project Title: MGB Eclipse Probe Detection of Category A Organisms | ||||
| 2003 | 2 | NIH | $962,638 | |
| Project Title: Genotyping with Minor-Groove-Binder-Containing Probes | ||||
| 2000 | 2 | NIH | $850,722 | |
| Project Title: Low Cost HIV Drug Resistance Monitoring | ||||
| 1997 | 1 | NIH | $100,000 | |
| Project Title: Selectively Binding Complementary Oligonucleotides | ||||
Key People / Management
William G Gerber -- President
Irina A Afonina
Eugeny A Lukhtanov
Jack R U'Ren
Robert B Wydro
Irina A Afonina
Eugeny A Lukhtanov
Jack R U'Ren
Robert B Wydro
Company News
There are no news available.
